<DOC>
	<DOC>NCT01518829</DOC>
	<brief_summary>the value of serum procalcitonin in differentiation between bacterial infection and non infectious inflammation in febrile HCC patients following locoeregional treatment for HCC.</brief_summary>
	<brief_title>Procalcitonin in Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>1. Hepatocellular carcinoma patients who will undergo TACE and/or radiofrequency. 2. Fever more than 38C after 48 hours post intervention. 1. HCC Patients who does not develop fever after intervention. 2. Proven infection elsewhere (e.g. UTI, chest infection..)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>hepatocellular carcinom</keyword>
	<keyword>postablation syndrom</keyword>
	<keyword>procalcitonin</keyword>
</DOC>